Research programme: cancer therapeutics - Array BioPharma/Loxo Oncology

Drug Profile

Research programme: cancer therapeutics - Array BioPharma/Loxo Oncology

Alternative Names: LOXO-102; LOXO-103; LOXO-104

Latest Information Update: 13 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Loxo Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Aug 2015 Loxo Oncology suspends IND filing for Cancer, until target validation is complete
  • 01 Apr 2014 Loxo Oncology and Array BioPharma expanded their previous agreement
  • 31 Jul 2013 Cancer therapeutics licensed to Loxo Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top